Corteva, Inc. (CTVA)
Valor JustoFundamental
50
Precio
$77.65
Capitalización Bursátil
$53.01B
Parte 1 · Cuánto vale la empresa
Resumen
Corteva sells seeds and crop-protection chemicals to farmers in about 110 countries. It was separated from DowDuPont in 2019, combining the old Pioneer seed genetics business with DuPont's agricultural chemicals. Its products help growers raise yield and fight weeds, insects and fungi on corn, soybeans and other row crops, sold mainly through independent dealers and a direct agency network built around the Pioneer brand.
Cómo genera ingresos
Revenue comes from two distinct product sales: branded seed with proprietary genetics and traits (Seed), and herbicides, insecticides and fungicides (Crop Protection). Both are booked when the dealer or farmer takes delivery, concentrated in the planting seasons of each hemisphere. Seed carries higher margins thanks to patented traits; Crop Protection is more exposed to generic competition once patents expire.
Ingresos por segmento
Corn, soybean and other seed sold under the Pioneer and Brevant brands, built on decades of proprietary germplasm and licensed and owned biotech traits.
Herbicides, insecticides, fungicides and biologicals, including newer active ingredients such as Zorvec and Arylex alongside older, more commoditized products.
Ventaja competitiva
Patentes y licencias · EstrechaCorteva's germplasm library reflects roughly 90 years of Pioneer breeding and field-testing data, and it holds thousands of patents including its own biotech traits rather than relying only on licenses. That data and IP base is hard to replicate quickly, but Bayer and Syngenta hold comparable positions, so the advantage is real but not exclusive.
Qué impulsa la demanda
CíclicoPurchases follow the planting calendar and farmers' expected income: commodity crop prices, input costs and weather in a given season decide how much a grower spends on seed and chemicals that year. A drought, a flood or a slump in corn and soybean prices can compress an entire season's demand quickly.
Riesgos clave
- Dependence on regulatory approvals — New seed traits and crop-protection products need approval from agencies such as the EPA, USDA and FDA and their equivalents abroad, and countries' rules on genetically modified crops differ and can change, delaying or blocking launches.
- Weather and climate variability — Abnormal weather in a major growing region — drought, excess rain, early frost — reduces both the acreage planted and the demand for crop inputs in that season, and the company cannot offset a bad season with sales elsewhere in the same window.
- Legacy environmental and litigation liabilities — Corteva carries obligations and litigation exposure inherited from its DuPont and Chemours history, including PFAS-related claims and crop-protection product liability suits, which can result in material costs unrelated to current operating performance.
- Competition from generics and major peers — Once a crop-protection active ingredient's patent expires, generic manufacturers can undercut it on price, and Corteva competes across both segments against a small number of very large rivals with comparable scale and research budgets.
- Execution risk of the planned Seed and Crop Protection separation — In October 2025 Corteva announced a plan to split into two independent listed companies. Carrying out that separation involves cost, management distraction and uncertainty over how each resulting company's shared costs and liabilities will be divided.
Los argumentos a favor
Buyers argue that Corteva's decades of proprietary germplasm and its own biotech traits let it capture more of the value chain than seed rivals who license traits from others, and that splitting Seed from Crop Protection could let each business be valued and managed on its own merits.
Los argumentos en contra
Sellers fear that both segments remain exposed to weather and commodity cycles outside the company's control, that generic competition keeps eroding Crop Protection margins, and that the planned separation adds execution risk and uncertain cost allocation on top of an already cyclical business.
Written by the editors, published on 18 de agosto de 2026
Direct competitors
Who this company fights with for the same customers
Generated on 18 de septiembre de 2026 with claude-haiku-4-5 — shared with all users
Bayer's Crop Science division is the only rival that matches Corteva across both of its businesses at once, selling corn and soybean seed with its own herbicide-tolerance traits alongside a full herbicide, fungicide and insecticide range to the same North and South American row-crop farmers.
Syngenta, owned by China's Sinochem and not publicly listed, competes head-on for the same farmer's wallet with a combined seed and crop-protection offer in the Americas, Europe and Asia, and is named as a competitor in Corteva's own 10-K.
BASF's Agricultural Solutions unit sells competing herbicides, fungicides and seed treatments plus its own soybean and canola seed-and-trait systems, going after the same crop-input budget on the same acres.
FMC is a pure crop-protection company whose insecticides and herbicides compete directly with Corteva's Crop Protection segment for the same treatments on corn, soybeans and specialty crops, especially in Brazil and the United States.
UPL is the largest supplier of off-patent crop-protection chemistry and undercuts Corteva's branded herbicides and fungicides once molecules lose exclusivity, particularly in Brazil, India and Eastern Europe.
KWS is a seed-only breeder that competes with Corteva's Pioneer brand for corn, sugar beet and cereal seed sales to European and North American farmers.
Balance y Liquidez
Ingresos
$17.81B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$1.01B
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$2.81B
Patrimonio Neto Total
$24.14B
Pasivo Total
$18.46B
Ratio de Liquidez
1.52
Cobertura de Intereses
-
Deuda/EBITDA
0.39
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$65.04
Precio Actual
$77.65
Margen de Seguridad
-19.4%
Rango de Valor Justo
$42.27 - $87.80
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
50.75
ROE
4.5%
Ratio P/B
2.06
P/FCF
82.37
Margen Bruto
49.5%
ROIC
-
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
-
WACC
7.8%
ROIC − WACC
-
Criterios de Análisis Fundamental
Superado (14)
- EPS shows upward trend
- Price CAGR 15.37%
- Gross Margin 49.5%
- P/B Ratio 2.06
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Analyst Consensus 69% Buy
- Earnings Surprise avg 20.6%
- Earnings Quality (OCF/NI) 1.20
- Share Dilution -2.0%
- Piotroski F-Score 6/9
Fallido (9)
- P/FCF 82.37
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 4.1%
- Revenue Growth 5Y 4.1%
- PEG Ratio 4.33
- Net Margin Trend 5.7% vs 8.2%
No disponible (4)
- ROIC NaN%
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Charles Victor Magro B.Sc. (Chem), MBA | CEO & Director | 55 |
| Mr. David P. Johnson | Executive VP & CFO | 57 |
| Dr. Samuel R. Eathington Ph.D. | Executive VP and Chief Technology & Digital Officer | 56 |
| Mr. Cornel B. Fuerer | Senior VP & Strategic Advisor | 58 |
| Mr. Judd M. O'Connor | Executive Vice President of Seed Business Unit | 54 |
| Mr. Brian Titus | VP, Controller & Principal Accounting Officer | 52 |
| Kimberly Booth | Vice President of Investor Relations | - |
| Dr. Jennifer Amy Johnson Ph.D. | Senior VP, Chief Legal & Public Affairs Officer and Corporate Secretary | 50 |
| Ms. Audrey Grimm | Senior VP & Chief People Officer | 44 |
| Mr. Jeffrey Rudolph | Senior VP & Chief Strategy Officer | 42 |
Riesgo de Auditoría
5
Riesgo del Consejo
3
Riesgo de Compensación
5
Riesgo de Derechos del Accionista
5
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-12
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-07-31
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-10-01
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for CTVA, sourced from Markets Gazette.
- 8/20/2026NEUTRALVylor Raises $1.1 Billion in Latest Pre-Spinoff Bond Sale
Vylor Inc., a subsidiary of Corteva Inc., successfully raised $1.1 billion through an investment-grade bond sale. The proceeds are earmarked to fund a payout to Corteva Inc., its soon-to-be former parent company, as Vylor prepares for a spinoff. This transaction highlights Vylor's ability to access capital markets effectively, but the direct financial impact on Corteva is primarily related to the distribution of funds rather than operational changes. Investors will monitor the terms of the spinoff and Vylor's future performance as an independent entity.
via Markets Gazette